CSPC Pharmaceutical Group Limited Announces Approval for ALMB-0166 Phase II Clinical Trial

Strategic Insights -

CSPC Pharmaceutical Group Limited, a leading Chinese pharmaceutical company, has made significant progress in the development of ALMB-0166, a novel humanized monoclonal antibody inhibitor targeting Connexin 43 (Cx43). The company has announced that ALMB-0166 has obtained approval from the National Medical Products Administration of China to conduct a Phase II clinical trial in patients with Parkinson's disease. This milestone marks a crucial step towards addressing the pressing need for novel therapeutic approaches to delay disease progression and improve patients' quality of life.

Key Takeaways:

  • ALMB-0166 is a first-in-class humanized monoclonal antibody inhibitor targeting Cx43, developed by CSPC's subsidiary AlaMab Therapeutics Inc. for the treatment of Parkinson's disease, acute ischemic stroke, acute spinal cord injury, and other neurological disorders.
  • Parkinson's disease is the world's second most common neurodegenerative disorder, affecting the substantia nigra and causing symptoms such as resting tremors, muscular rigidity, bradykinesia, and postural instability.
  • Current therapeutic drugs and approaches provide only symptomatic relief without reversing disease progression or achieving a cure, underscoring the urgent need for novel therapeutic drugs and approaches.
  • ALMB-0166 exerts its effect by targeting Cx43 hemichannels, inhibiting the release and spread of neuroinflammatory mediators, and maximizing neuroprotection.
  • Preclinical studies demonstrated that ALMB-0166 significantly prevented dopamine depletion in the brain, restored behavioral performance and functional capacity, and exhibited a favorable dose-response relationship.
  • The Group will make every effort to advance the clinical development of ALMB-0166 across multiple indications and strive to bring it to the market as early as possible.

Statistics:

  • ALMB-0166 has potential applications in the treatment of Parkinson's disease, acute ischemic stroke, acute spinal cord injury, and other neurological disorders.
  • Parkinson's disease is the world's second most common neurodegenerative disorder, characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra.
  • The clinical manifestations of Parkinson's disease include motor symptoms such as resting tremors, muscular rigidity, bradykinesia, and postural instability, as well as non-motor symptoms including sleep disorders, cognitive impairment, and psychiatric disturbances.

Sources:

  • CSPC Pharmaceutical Group Limited [2025, 09 15] https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0915/2025091500980.pdf